AMYRIS, INC. REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
- Core revenue exceeded guidance by 12% in Q1 2023, reaching $56.1 million. Cash operating expense decreased by 4% compared to Q1 2022 and by 24% compared to Q4 2022. The company completed a strategic partnership with Givaudan, receiving $200 million upfront cash.
- None.
- Core revenue of
exceeded Q1 guidance of$56.1 million $49.9 million - Cash operating expense down
4% compared to Q1 2022 and down24% versus Q4 2022 - Completed strategic partnership with Givaudan on April 3 for
upfront cash$200 million
Q1 2023 Core revenue of
The company continues to execute its strategic agenda with a keen focus on cost efficiency, capital structure, and liquidity. The company is in the process of a strategic review of all aspects of its cost structure in support of the company's Fit-to-Win initiatives, with the objective to accelerate cost and efficiency improvements. Use of cash for operating and investing activities decreased sequentially for each of the past five quarters beginning with
The company expanded its Technology Access partnerships by closing the strategic transaction with Givaudan for the worldwide licensing of certain cosmetic ingredients, the highest per molecule transaction completed in the company's history. The transaction yielded up to
"During Q1, we were very focused on our liquidity and cost control efforts," commented John Melo, President and Chief Executive Officer. "We expanded the Fit-to-Win scope to all aspects of our operations and entered into a strategic review of our cost structure and liquidity plans to continue to support growth across the portfolio and achieve profitability. We have much more to do on our Fit-to-Win agenda. To fully leverage our assets and drive enterprise value, we are focused on efficiency, lowering costs, and simplifying our portfolio."
Income Statement
| Q122A | Q222A | Q322A | Q422A | 2022A | Q123A | YoY% | QoQ % | |||
Consumer | 34.6 | 43.0 | 46.6 | 52.8 | 176.9 | 34.2 | -1 % | -35 % | |||
Technology Access | 23.2 | 22.2 | 24.6 | 23.0 | 92.9 | 21.9 | -5 % | -5 % | |||
Core revenue1 | 57.7 | 65.2 | 71.1 | 75.8 | 269.8 | 56.1 | -3 % | -26 % | |||
Non-GAAP Gross Profit | 10.6 | 11.1 | 6.7 | (6.2) | 22.2 | 11.6 | 9 % | 288 % | |||
Non-GAAP Cash Operating Expense | (117.1) | (136.7) | (137.8) | (148.3) | (539.9) | (112.8) | 4 % | 24 % | |||
Adjusted EBITDA | (106.5) | (125.6) | (131.0) | (154.5) | (517.7) | (101.2) | 5 % | 34 % |
1 Core revenue comprises Consumer and Technology Access revenue. Technology Access includes ingredient product revenue, R&D collaboration, and technology licenses. Core revenue excludes strategic transactions. Totals may not foot due to rounding.
Q1 2023 Financial Highlights
- Core revenue of
decreased$56.1 million 3% compared to Q1 2022. Core revenue included Consumer revenue of , which decreased$34.2 million 1% relative to Q1 2022, and Technology Access revenue of , which decreased$21.9 million 5% compared to Q1 2022. - Q1 Consumer revenue decline was driven by lower Biossance® revenue due to lower marketing and media spend, offset in part by the launch of our 4U by TiaTM brand at Walmart as well as increased MenoLabs® direct-to-consumer revenue. In Q1 2023, direct-to-consumer sales represented
48% of total consumer revenue, compared to53% in Q4 2022. Biossance®, Pipette®, JVN, and Rose Inc.® products were available in more than 15,750 physical locations compared to approximately 3,000 in Q1 2022. - Q1 Technology Access revenue included Ingredients product revenue of
, which decreased$8.9 million 18% compared to Q1 2022, reflecting continuing supply and working capital constraints as the business transitioned from higher cost toll manufacturing to lower cost internal sourcing from the new fermentation plant inBrazil . R&D collaboration revenue of improved relative to the prior year with growth driven by several new contract research programs. Technology license revenue from earn-outs totaled$3.6 million .$9.5 million - Non-GAAP gross profit of
in Q1 2023 was$11.6 million 21% of revenue. Non-GAAP gross profit improved from or$10.6 million 18% of revenue in Q1 2022, reflecting lower freight expenses as well as a favorable mix of higher margin revenue. - Non-GAAP cash operating expense of
was$112.8 million 4% lower than Q1 2022 and24% lower than Q4 2022, primarily due to lower marketing and media spend as a result of cost focus and working capital constraints. - Adjusted EBITDA of
( represented a$101.2) million improvement over Q1 2022 and a$5.3 million sequential improvement over Q4 2022 due to lower operating expenses, including lower marketing and media spend.$53.3 million - Q1 2023 net loss was
($193.3 million loss per diluted share or$0.53 loss per diluted share when excluding the below referenced items) compared to a net loss of$0.34 ($107.3 million loss per diluted share) in Q1 2022. This included a favorable non-cash change in fair value of acquisition-related contingent consideration of$0.37 ($28.5 million per diluted share) and non-cash asset impairments totaling$0.08 ($95.4 million per diluted share) related to exiting the EcoFabulous brand and reorganizing the Beauty Labs business. In addition, non-cash mark-to-market adjustments related to changes in the fair value of debt and derivatives were$0.26 unfavorable in Q1 2023 ($3.6 million per diluted share) and$0.01 favorable in Q1 2022 ($22.6 million per diluted share).$0.07 - Total cash at the end of Q1 2023 was
compared to$17.5 million at the end of Q4 2022.$70.6 million
Financial Status and Outlook
Our current outlook for the full year 2023, including revenue guidance provided by the company on March 15, 2023, remains unchanged.
In connection with the company's ongoing strategic review, as previously communicated on April 24, 2023, the company is focused on cost efficiency, capital structure, and liquidity required to fund the business.
The company updated its going concern disclosure in its quarterly report on Form 10-Q and has signed forbearance agreements with the company's lenders, Foris Ventures, LLC, Perrara Ventures, LLC, and DSM Finance B.V. relating to the maturity of an aggregate
FINANCIAL RESULTS AND NON-GAAP INFORMATION
To supplement our financial results and guidance presented in accordance with
Non-GAAP financial information is not prepared under a comprehensive set of accounting rules, and therefore, should only be read in conjunction with financial information reported under GAAP in order to understand Amyris' operating performance. A reconciliation of the non-GAAP financial measures presented in this release to the most directly comparable GAAP financial measure, is provided in the tables attached to this press release.
Our Non-GAAP financial measures include the following:
Non-GAAP Gross Profit is calculated as GAAP revenue less cost of products sold excluding certain inventory write-offs, manufacturing capacity fee adjustments, stock-based compensation expense, depreciation, and amortization.
Non-GAAP Cash Operating Expense is calculated as GAAP Operating Expense excluding stock-based compensation, depreciation, amortization, M&A transaction expense, change in fair value of acquisition-related contingent consideration, restructuring, and impairment.
EBITDA is calculated as GAAP net income (loss) excluding interest expense, income taxes, depreciation and amortization.
Adjusted EBITDA is calculated as EBITDA excluding income/loss attributable to noncontrolling interest, gain/loss from change in fair value of derivative instruments, gain/loss from change in fair value of debt, other income/expense, gain/loss from investment in affiliate, inventory write-offs, M&A transaction expense, stock-based compensation expense, manufacturing capacity fee adjustment, change in fair value of acquisition-related contingent consideration, restructuring, and impairment.
About Amyris
Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology company, transitioning the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients through fermentation and the company's proprietary Lab-to-MarketTM technology platform. This Amyris platform leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the company to rapidly bring new innovation to market at commercial scale. Amyris ingredients are included in over 20,000 products from the world's top brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that is constantly evolving to meet the growing demand for sustainable, effective and accessible products. For more information, please visit http://www.amyris.com.
Amyris, the Amyris logo, EcoFabulous and Lab-to-Market are trademarks or registered trademarks of Amyris, Inc. or its subsidiaries in the
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as Amyris' successful execution of its strategic agenda including Fit-to-Win initiatives; its 2023 outlook and goals, including cost reduction initiatives, growth, profitability and other financial and business goals; and Amyris' expectations regarding the ongoing strategic review of its cost structure and 2023 plan and the timing of completion thereof. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris' liquidity and ability to operate as a going concern, risks related to its financing activities including successfully obtaining waivers and amendments of outstanding loan agreements, risks related to potential delays or failures in completing planned strategic transactions and dispositions, risks related to potential delays or failures in development, regulatory approval, launch, production and commercialization of products, risks related to global economic trends, inflation and policy measures undertaken to address inflation, the COVID-19 pandemic and any other geopolitical events, including the
Financial Tables Follow
Amyris, Inc. | ||
CONSOLIDATED BALANCE SHEETS | ||
(In thousands) | March 31, | December |
Assets | ||
Current assets: | ||
Cash and cash equivalents | $ 11,245 | $ 64,437 |
Restricted cash | 71 | 71 |
Accounts receivable, net | 36,842 | 45,775 |
Accounts receivable - related party, net | 10,836 | 6,608 |
Contract assets | 3,872 | 806 |
Contract assets - related party | 33,679 | 36,638 |
Inventories | 109,021 | 111,880 |
Prepaid expenses and other current assets | 38,095 | 40,146 |
Total current assets | 243,661 | 306,361 |
Property, plant and equipment, net | 189,645 | 182,224 |
Restricted cash, noncurrent | 6,135 | 6,090 |
Recoverable taxes from Brazilian government entities | 30,189 | 29,472 |
Right-of-use assets under financing leases, net | 147 | 152 |
Right-of-use assets under operating leases, net | 100,721 | 97,216 |
Goodwill | 50,456 | 142,575 |
Intangible assets, net | 45,063 | 46,938 |
Other assets | 13,662 | 13,904 |
Total assets | $ 679,679 | $ 824,932 |
Liabilities, Mezzanine Equity and Stockholders' Deficit | ||
Current liabilities: | ||
Accounts payable | $ 200,067 | $ 190,486 |
Accrued and other current liabilities | 81,068 | 73,565 |
Financing lease liabilities | 14 | 13 |
Operating lease liabilities | 2,484 | 2,255 |
Contract liabilities | 33 | 26 |
Debt, current portion | 1,968 | 1,916 |
Related party debt, current portion | 185,160 | 118,886 |
Total current liabilities | 470,794 | 387,147 |
Long-term debt, net of current portion | 675,855 | 674,891 |
Related party debt, net of current portion | 77,962 | 97,350 |
Financing lease liabilities, net of current portion | 44 | 48 |
Operating lease liabilities, net of current portion | 90,986 | 86,195 |
Derivative liabilities | 4,140 | 5,403 |
Acquisition-related contingent consideration | 2,241 | 34,555 |
Other noncurrent liabilities | 5,725 | 7,053 |
Total liabilities | 1,327,747 | 1,292,642 |
Commitments and contingencies | ||
Mezzanine equity: | ||
Contingently redeemable common stock | - | 5,000 |
Contingently redeemable noncontrolling interest | 26,058 | 28,892 |
Stockholders' deficit: | ||
Common stock | 37 | 36 |
Additional paid-in capital | 2,465,802 | 2,455,567 |
Accumulated other comprehensive loss | (56,682) | (64,114) |
Accumulated deficit | (3,073,520) | (2,880,178) |
Total Amyris, Inc. stockholders' deficit | (664,363) | (488,689) |
Noncontrolling interest | (9,763) | (12,913) |
Total stockholders' deficit | (674,126) | (501,602) |
Total liabilities, mezzanine equity and stockholders' deficit | $ 679,679 | $ 824,932 |
Amyris, Inc. | ||
CONSOLIDATED STATEMENTS OF OPERATIONS | ||
Three Months Ended | ||
(In thousands, except shares and per share amounts) | 2023 | 2022 |
Revenue: | ||
Renewable products | $ 40,224 | $ 43,465 |
Licenses and royalties | 9,482 | 9,313 |
Collaborations, grants and other | 6,377 | 4,931 |
Total revenue | 56,083 | 57,709 |
Cost and operating expenses: | ||
Cost of products sold | 51,081 | 48,995 |
Research and development | 26,765 | 26,358 |
Sales, general and administrative | 95,870 | 106,916 |
Change in fair value of acquisition-related contingent consideration | (28,503) | - |
Restructuring | 1,013 | - |
Impairment | 95,386 | - |
Total cost and operating expenses | 241,612 | 182,269 |
Loss from operations | (185,529) | (124,560) |
Other income (expense): | ||
Interest expense | (12,983) | (5,263) |
Gain from change in fair value of derivative instruments | 1,263 | 1,815 |
Gain (loss) from change in fair value of debt | (4,854) | 20,796 |
Other expense, net | (533) | (3,052) |
Total other income (expense), net | (17,107) | 14,296 |
Loss before income taxes and loss from investment in affiliate | (202,636) | (110,264) |
Benefit from income taxes | 860 | 820 |
Loss from investment in affiliate | - | (789) |
Net loss | (201,776) | (110,233) |
Loss attributable to noncontrolling interest | 8,434 | 2,928 |
Net loss attributable to Amyris, Inc. common stockholders | $ (193,342) | $ (107,305) |
Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic | 365,603,738 | 312,896,452 |
Loss per share attributable to common stockholders, basic | $ (0.53) | $ (0.34) |
Weighted-average shares of common stock outstanding used in computing loss per share of common stock, diluted | 365,603,738 | 323,711,682 |
Loss per share attributable to common stockholders, diluted | $ (0.53) | $ (0.37) |
Amyris, Inc. | ||
EBITDA AND ADJUSTED EBITDA | ||
Three Months Ended | ||
(In thousands) | 2023 | 2022 |
Net loss attributable to Amyris, Inc. common stockholders | $ (193,342) | $ (107,305) |
Interest expense | 12,983 | 5,263 |
Income taxes | (860) | (820) |
Depreciation and amortization | 5,851 | 3,292 |
EBITDA | (175,368) | (99,570) |
Inventory write-off | 4,211 | (94) |
Change in fair value of acquisition-related contingent consideration | (28,503) | - |
Restructuring | 1,013 | - |
Impairment | 95,386 | - |
Manufacturing capacity fee adjustment | - | 1,412 |
M&A transaction expense | 566 | 1,835 |
Stock-based compensation expense | 5,785 | 11,588 |
Gain from change in fair value of derivative instruments | (1,263) | (1,815) |
Loss (gain) from change in fair value of debt | 4,854 | (20,796) |
Other expense, net | 533 | 3,052 |
Loss from investment in affiliate | - | 789 |
Loss attributable to noncontrolling interest | (8,434) | (2,928) |
Adjusted EBITDA | $ (101,220) | $ (106,527) |
Amyris, Inc. | ||
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION | ||
Three Months Ended March 31, | ||
(In thousands) | 2023 | 2022 |
NON-GAAP GROSS PROFIT | ||
Revenue | ||
Renewable products | $ 40,224 | $ 43,465 |
Licenses and royalties | 9,482 | 9,313 |
Collaborations, grants and other | 6,377 | 4,931 |
Total revenue | $ 56,083 | $ 57,709 |
Cost of products sold | $ 51,081 | $ 48,995 |
Manufacturing capacity fee adjustment | - | (1,412) |
Inventory write-off | (4,211) | 94 |
Stock-based compensation expense | (66) | (78) |
Depreciation and amortization | (2,324) | (490) |
Non-GAAP cost of products sold | $ 44,480 | $ 47,109 |
Non-GAAP gross profit | $ 11,603 | $ 10,600 |
Non-GAAP gross profit % | 21 % | 18 % |
NON-GAAP CASH OPERATING EXPENSE | ||
Research and development expense | $ 26,765 | $ 26,358 |
Sales, general and administrative expense | 95,870 | 106,916 |
Change in fair value of acquisition-related contingent consideration | (28,503) | - |
Restructuring | 1,013 | - |
Impairment | 95,386 | - |
GAAP operating expense | 190,531 | 133,274 |
Stock-based compensation expense | (5,719) | (11,510) |
Depreciation and amortization | (3,527) | (2,802) |
M&A transaction expense | (566) | (1,835) |
Change in fair value of acquisition-related contingent consideration | 28,503 | - |
Restructuring | (1,013) | - |
Impairment | (95,386) | - |
Non-GAAP cash operating expense |
View original content to download multimedia:https://www.prnewswire.com/news-releases/amyris-inc-reports-first-quarter-2023-financial-results-301820072.html
SOURCE Amyris, Inc.
FAQ
What was the Q1 2023 core revenue for Amyris, Inc.?
How did the cash operating expense change in Q1 2023 compared to Q1 2022?